Outcomes of reduction hepatectomy combined with postoperative multidisciplinary therapy for advanced hepatocellular carcinoma

doi:10.4240/wjgs.v13.i10.1245

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 10

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2940)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-5) series.

Item

Count

PDF

148

WORD

143

HTML

1324

Figures (1-2)

185

Tables (1-5)

141

Sum=1941

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

342

Download

657

Sum=999

Oct 27, 2021 (publication date) through Apr 24, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Surg. Oct 27, 2021; 13(10): 1245-1257
Published online Oct 27, 2021. doi: 10.4240/wjgs.v13.i10.1245

Table 2 Peri-surgical treatment

Preoperative treatment
No treatment	24
TAI	4
TAI + ERT	1
TAI + TKI¹ + ERT	1
Postoperative treatment	Total	POCR (+)
TAI + hepatectomy + lung resection + chemo	1	1
Hepatectomy + chemo + TAI + ERT	1	1
Lung resection + LAT + TAI + chemo + ERT	1	1
Lung resection + LAT	1	0
Brain tumor resection + TAI + TKI² + chemo + ERT	1	0
LAT + TAI + ERT	2	2
TAI + TKI³ + chemo ( + ERT)	3	0
TAI + TKI⁴	2	0
TAI + chemo ( + ERT)	6	1
TAI ( + ERT)	9	2
ERT	1	0
No treatment	1	0
Unknown	1	0
Total	30	8

¹TKI: Sorafenib (n = 1).

²TKI: Sorafenib (n = 1).

³TKI: Sorafenib (n = 1), lenvatinib (n = 1), sorafenib + lenvatinib (n = 1).

⁴TKI: Sorafenib (n = 1), sorafenib + lenvatinib (n = 1). TAI: Transarterial infusion; ERT: External beam radiotherapy; TKI: Tyrosine kinase inhibitors; LAT: Local ablation therapy.

Citation: Asahi Y, Kamiyama T, Kakisaka T, Orimo T, Shimada S, Nagatsu A, Aiyama T, Sakamoto Y, Kamachi H, Taketomi A. Outcomes of reduction hepatectomy combined with postoperative multidisciplinary therapy for advanced hepatocellular carcinoma. World J Gastrointest Surg 2021; 13(10): 1245-1257
URL: https://www.wjgnet.com/1948-9366/full/v13/i10/1245.htm
DOI: https://dx.doi.org/10.4240/wjgs.v13.i10.1245